Mr. Rashid Bux reports

BIOMARK ANNOUNCES WARRANT EXTENSION AND GRANTING OF OPTIONS

Biomark Diagnostics Inc. intends to amend the terms of 5,062,000 the non-broker warrants issued to a private placement financing that closed on May 4, 2022. The warrants currently carry an exercise price per share of 45 cents and are scheduled to expire on May 4, 2024.

The company proposes to extend its term by two years such that the warrants will be exercisable until May 4, 2026, at the same exercise price per share of 45 cents. All other terms of the warrants will remain unchanged. None of these warrants have been exercised to date. warrant holders are advised that replacement warrant certificates will not be issued and that the original warrant certificate must be presented to the company to effect the exercise of the warrants. Holders of the warrants may contact the company at info@Biomarkdiagnostics.com, should they have any questions or wish to exercise their warrants.

In addition, the company granted 4,625,000 stock options to key employees, management team, scientific advisers and consultants. Each option grants the holder the right to purchase one common share at a purchase price of 45 cents per common share for a period of three years from the date of issuance. The options shall vest according to the following vesting schedule: 25 per cent shall vest immediately upon issue; 25 per cent shall vest upon the date that is six months from the date of issue; 25 per cent shall vest upon the date that is 12 months from the date of issue; and the remaining 25 per cent shall vest upon the date that is 18 months from the date of issue. All terms and conditions of these options will be in accordance with the terms of the company's stock option plan (2022) and subject to approval by the board of directors. The grant of stock options has been designed to help the company attract and retain talented employees, consultants, advisers and directors, and obtain the required consulting service from domain experts while preserving the cash for operating purposes.

About Biomark Diagnostics Inc.

Biomark is a liquid biopsy company developing a molecular diagnostic technology platform that leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the presymptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. While the company's current focus is on the commercialization of its liquid biopsy test for early detection of lung, it has plans to expand into other hard-to-detect and treat cancers such as brain, ovarian and pancreatic.

We seek Safe Harbor.